Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Combined With Chemotherapy in Unresectable Soft Tissue Sarcoma
NCT04126811Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jun 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Rivoceranib in soft tissue sarcoma (STS) (3 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT04126811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04126811.